A Phase 1 interventional study of Treatment A and Treatment B in Healthy, sponsored by Tonix Pharmaceuticals, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-11.
Sponsored by Tonix Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The trial is designed to assess the safety and tolerability of TNX-102 2.4 mg and to compare the bio-availability of TNX-102 2.4 mg and cyclobenzaprine 5 mg tablets under fasting or fed conditions.
Single-center, randomized, open-label, single-dose, three-way-crossover trial is designed to assess the safety and tolerability of TNX-102 2.4 mg (a dose based on the results of a previous Phase 2a, proof-of-concept study - VPI-CY-0001.1) and to compare the rate and extent of absorption of TNX-102 2.4 mg and cyclobenzaprine 5 mg tablets under fasting or fed conditions.
Tonix Pharmaceuticals, Inc. is the lead sponsor of 34 studies on the registry; 1 is open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 12 (71%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: Healthy adults
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 x TNX-102 2.4 mg gelcap under fasting conditions
Drug: Treatment A
1 x cyclobenzaprine 5 mg immediate release (IR) tablet under fasting conditions
Drug: Treatment B
1 x TNX-102 2.4 mg gelcap under fed conditions
Drug: Treatment C
TNX-102 2.4 mg - 1 gelcap once under fasting conditions.
Also known as: cyclobenzaprine HCl
Cyclobenzaprine 5 mg, 1 tablet once under fasting conditions
Also known as: cyclobenzaprine HCl
TNX-102 2.4 mg, 1 gelcap once given under fed conditions.
Also known as: cyclobenzaprine HCl
Mean Plasma Concentration (AUC) of Cyclobenzaprine
Blood samples were collected pre-dose, 30 min, 1, 1.5, 2, 2.5, 3, 3.33, 3.67, 4, 4.67, 5, 5.5, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose for each treatment period.
Time frame: 0 to 96 hours
Incidences of Adverse Events
Every adverse events occurring during the study period will be reported.
Time frame: Continuously until the end (day 5) of each study period + 8-10 days after end of last period (total duration: about 1 month)
| Milestone | Treatment A First, Then B, Then C | Treatment A First, Then C, Then B | Treatment B First, Then A, Then C | Treatment B First, Then C, Then A | Treatment C First, Then A, Then B | Treatment C First, Then B, Then A |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 5 | 5 |
| Completed | 4 | 5 | 5 | 5 | 5 | 5 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected pre-dose, 30 min, 1, 1.5, 2, 2.5, 3, 3.33, 3.67, 4, 4.67, 5, 5.5, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose for each treatment period.
| pg.hr/mL | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Mean Plasma Concentration (AUC) of Cyclobenzaprine | 47,074.19 (30288.11 to 63860.27) | 94,874.26 (60588.45 to 129160.07) | 50,263.16 (30725.75 to 69800.57) |
Every adverse events occurring during the study period will be reported.
| Participants | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Subjects with Treatment-Emergent Adverse Events | 14 | 15 | 10 |
| Subjects with Serious Adverse Events | 0 | 0 | 0 |
| Subjects discontinued due to adverse event | 0 | 0 | 0 |
Collected over 2 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | 0/30 (0%) | 0/30 (0%) | 14/30 (46.7%) |
| Treatment B | 0/30 (0%) | 0/30 (0%) | 15/30 (50%) |
| Treatment C | 0/30 (0%) | 0/30 (0%) | 10/30 (33.3%) |
| Event | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| SomnolenceNervous system disorders | 3/30 | 11/30 | 2/30 |
| ConstipationGastrointestinal disorders | 3/30 | 1/30 | 1/30 |
| Abdominal distensionGastrointestinal disorders | 2/30 | 0/30 | 1/30 |
| Blood Pressure increasedInvestigations | 2/30 | 1/30 | 1/30 |
| catheter site painGeneral disorders | 1/30 | 0/30 | 2/30 |
| PalpitationsCardiac disorders | 1/30 | 0/30 | 0/30 |
| Ear DiscomfortEar and labyrinth disorders | 0/30 | 0/30 | 1/30 |
| PhotophobiaEye disorders | 0/30 | 1/30 | 0/30 |
| Abdominal PainGastrointestinal disorders | 1/30 | 0/30 | 0/30 |
| DiarrhoeaGastrointestinal disorders | 0/30 | 0/30 | 1/30 |
| Age, Categorical(Participants) | All Study Participants |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 30 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | All Study Participants |
|---|---|
| Female | 8 |
| Male | 22 |
| Region of Enrollment(participants) | All Study Participants |
|---|---|
| Canada | 30 |
The record gives a start of Nov 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2018, 6 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclobenzaprine